FindTrial
Sign In

To test the efficacy of a biocompatible chemical in masking antigens that may be clinically significant in causing untoward transfusion reactions, present on red blood cells.

Establishing the efficacy of masking the clinically significant blood group antigens on human RBCs by a biocompatible material - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/06/089051
Enrollment
30
Registered
2025-06-18
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Control Intervention1: NIL: NIL

Sponsors

TERUMO PENPOL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: RBC samples from healthy non remunerated voluntary blood donors.

Exclusion criteria

Exclusion criteria: RBC samples that are reactive for Transfusion Transmitted Infections or positive for Direct Coombs Test will be excluded.

Design outcomes

Primary

MeasureTime frame
The study design will aid in determining the optimal concentration of bio compatible material which can effectively mask red cell antigen. The red cells post coating should retain their structure and functionality.Timepoint: Baseline , 24 hours—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactBismita BIswabandini

Kasturba Medical College

shamee.girish@manipal.edu9743489837

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026